Tripathi A K, Verma S P, Kumar Nidhish
Department of Clinical Hematology, King Georges Medical University, Lucknow, UP India.
Indian J Hematol Blood Transfus. 2017 Sep;33(3):316-320. doi: 10.1007/s12288-016-0755-y. Epub 2016 Nov 29.
Tyrosine kinase inhibitors (TKI's) are currently the drug of choice for management of chronic myeloid leukemia. Imatinib is the most commonly used first line TKI in India. Mutations leading to resistance to imatinib are the most common cause for imatinib failure. We studied pattern of kinase domain mutations in 40 patients of CML who either lost their response or did not achieve it in defined timepoints. Loss of molecular response was the most common indication for asking mutation analysis. Sixteen patients were found to have detectable mutations. M351T was the most common tyrosine kinase mutation followed by Y253H and H396R. Two patients had 2 mutations simultaneously. M351T is the most common mutation in our patient population.
酪氨酸激酶抑制剂（TKIs）目前是慢性髓性白血病治疗的首选药物。伊马替尼是印度最常用的一线TKI。导致对伊马替尼耐药的突变是伊马替尼治疗失败的最常见原因。我们研究了40例慢性髓性白血病患者的激酶结构域突变模式，这些患者在规定的时间点失去反应或未达到反应。分子反应丧失是进行突变分析的最常见指征。16例患者被发现有可检测到的突变。M351T是最常见的酪氨酸激酶突变，其次是Y253H和H396R。两名患者同时有两种突变。M351T是我们患者群体中最常见的突变。
